Loading the section…
The price of Harmony Biosciences Holdings, Inc. (HRMY) on October 9, 2026 is 40.28 USD, +1.72% on the day. Over 52 weeks the stock traded between 25.52 USD and 43.49 USD; the price now sits 82% of the way up that range. Over the past year the price changed by +51.66%. The P/E ratio is 16.0, which is below the sector median (25.0). Market capitalization is 2.33 billion USD, rank 65 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +52.81 %
Harmony Biosciences Holdings, Inc. trades on Nasdaq under the ticker HRMY. The company belongs to the Health care sector. The trading history on this page starts on 19 August 2020.
Over the past 52 weeks HRMY has traded between 25.52 $ and 43.49 $. As of 9 October 2026 the price stood 82.14 % of the way from the 52-week low to the high.
Over one year HRMY shares rose 51.66 %; over six months they rose 39.43 %. Volatility over 90 days is 38.80 %. Dividends are not included: this is price change only, as of 9 October 2026.
HRMY trades at a price-to-earnings ratio of 16.0, below the sector median of 25.0. Price to sales is 2.6, below the sector median of 4.0. Price to book is 2.6, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 39.53 | 40.57 | 39.51 | 40.28 | 487,100 |
| 8 October 2026 | 39.14 | 39.89 | 38.68 | 39.60 | 865,000 |
| 7 October 2026 | 39.27 | 39.86 | 39.10 | 39.34 | 547,000 |
| 6 October 2026 | 40.09 | 40.35 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Harmony Biosciences Holdings, Inc. (HRMY) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 899.1m $, net income was 145.6m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING, PA, 19462, US
Harmony Biosciences Holdings, Inc. reported revenue of 899M $ and net income of 146M $ over the last four quarters. Net margin is 16.20 %. Revenue changed by +20.71 % year over year. Earnings per share are 2.48 $. Market capitalisation is 2.3B $.
HRMY has a return on equity of 16.00 %, above the sector median of −41.68 %. Return on assets is 11.45 %, above the sector median of −32.11 %. Operating margin is 21.08 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 38.91 |
| 39.36 |
| 507,300 |
| 5 October 2026 | 39.76 | 40.77 | 39.51 | 39.92 | 897,900 |
| 2 October 2026 | 39.78 | 40.62 | 39.25 | 39.64 | 916,700 |
| 1 October 2026 | 39.58 | 40.46 | 39.08 | 39.57 | 1M |
| 30 September 2026 | 39.30 | 39.56 | 38.72 | 39.26 | 667,500 |
| 29 September 2026 | 39.87 | 40.52 | 39.15 | 39.29 | 786,700 |
| 28 September 2026 | 41.29 | 41.54 | 39.54 | 40.01 | 874,400 |
| 25 September 2026 | 41.37 | 41.60 | 40.89 | 41.26 | 556,900 |
| 24 September 2026 | 40.63 | 41.79 | 40.00 | 41.16 | 906,400 |
| 23 September 2026 | 41.61 | 42.08 | 39.72 | 40.48 | 1M |
| 22 September 2026 | 42.10 | 42.37 | 41.36 | 41.53 | 577,900 |
| 21 September 2026 | 41.87 | 42.52 | 41.20 | 42.10 | 839,000 |
| 18 September 2026 | 42.57 | 43.27 | 41.90 | 42.02 | 4M |
| 17 September 2026 | 42.59 | 43.01 | 42.10 | 42.74 | 641,400 |
| 16 September 2026 | 42.28 | 43.05 | 42.06 | 42.21 | 2M |
| 15 September 2026 | 41.64 | 42.19 | 40.94 | 42.17 | 1M |
| 14 September 2026 | 41.93 | 42.25 | 41.48 | 41.54 | 1M |